Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNLX Genelux Corporation

Not Yet Opened 11-05 16:00:00 EST

1.82

-0.14

-7.14%

盘后1.91

+0.09+4.95%

17:22 EST

High1.94	Low1.77	Vol228.56K
Open1.94	D1 Closing1.96	Amplitude8.67%
Mkt Cap82.35M	Tradable Cap67.16M	Total Shares45.25M
T/O420.75K	T/O Rate0.62%	Tradable Shares36.90M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GNLX","market":"US","secType":"STK","nameCN":"Genelux Corporation","latestPrice":1.82,"timestamp":1793912400000,"preClose":1.96,"halted":0,"volume":228563,"hourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.82,"latestTime":"17:22 EST","volume":804,"amount":1519.2227,"timestamp":1793917365580,"change":0.09,"changeRate":0.049451,"amplitude":0.049451},"delay":0,"changeRate":-0.07142857142857138,"floatShares":36899500,"shares":45245335,"eps":-0.86226,"marketStatus":"Not Yet Opened","change":-0.14,"latestTime":"11-05 16:00:00 EST","open":1.94,"high":1.94,"low":1.77,"amount":420746.8386739,"amplitude":0.086735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.86226,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793955600000},"marketStatusCode":0,"adr":0,"listingDate":1674709200000,"exchange":"NASDAQ","adjPreClose":1.96,"preHourTrading":{"tag":"盘前","latestPrice":1.96,"preClose":1.96,"latestTime":"09:04 EST","volume":2,"amount":3.92,"timestamp":1793887497529,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":1.91,"preClose":1.82,"latestTime":"17:22 EST","volume":804,"amount":1519.2227,"timestamp":1793917365580,"change":0.09,"changeRate":0.049451,"amplitude":0.049451},"volumeRatio":0.785506,"impliedVol":2.21,"impliedVolPercentile":0.7291},"requestUrl":"/m/hq/s/GNLX","defaultTab":"news","newsList":[{"id":"2668093367","title":"Genelux assumed with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2668093367","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668093367?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:00","pubTimestamp":1789588818,"startTime":"0","endTime":"0","summary":"Lucid Capital analyst Dev Prasad assumed coverage of Genelux (GNLX) with a Buy rating and price target of $18, up from $10. The share setup is attr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genelux-assumed-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genelux-assumed-with-a-buy-at-lucid-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GNLX","LCDL","BK4099","BK4551","BK4596","BK4139","LCID","LCIZ","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666153080","title":"Genelux publishes case report from dose escalation portion of OLVI-VEC-202-SCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2666153080","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666153080?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:10","pubTimestamp":1788984641,"startTime":"0","endTime":"0","summary":"Genelux (GNLX) announced the publication of a case report from the ongoing Phase 1b dose escalation portion of its Phase 1b/2 OLVI-VEC-202-SCLC tri...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genelux-publishes-case-report-from-dose-escalation-portion-of-olvi-vec-202-sclc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genelux-publishes-case-report-from-dose-escalation-portion-of-olvi-vec-202-sclc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNLX","OLVI","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666537114","title":"Genelux Reports 16.7-Month PFS in Phase 1b/2 Olvi-Vec Trial Case Study for Platinum-Relapsed SCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2666537114","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666537114?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984090,"startTime":"0","endTime":"0","summary":"Genelux reports 16.7-month PFS in phase 1b/2 Olvi-Vec trial case study for platinum-relapsed SCLCGenelux flagged a peer-reviewed case report from its OLVI-VEC-202-SCLC study in platinum-relapsed small","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nNDL8m8xYS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","SG9999014021.USD","IE00BN0W2V16.EUR","NDAQ","BK4585","BK4588","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","LU2095319765.USD","GNLX","BK4139","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4112","IE00BQXX3D17.EUR","IE00BN0W2W23.USD","LU0314104364.USD","IE00BQXX3F31.USD","LU2210150020.SGD","BCDF","IE00BN0W2T93.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666053779","title":"Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666053779","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666053779?lang=en_us&edition=fundamental","pubTime":"2026-09-10 04:01","pubTimestamp":1788984060,"startTime":"0","endTime":"0","summary":"-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3359047/0/en/genelux-announces-publication-of-a-deep-and-durable-response-in-a-platinum-relapsed-small-cell-lung-cancer-patient-following-systemically-delivered-olvi-vec-primed-immunochemothera.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4195","BK4139","GNLX","PFS","PLTM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659116094","title":"Genelux Publishes Corporate Presentation Highlighting Olvi-Vec Late-Stage Ovarian Cancer Program Focused on Platinum Sensitization","url":"https://stock-news.laohu8.com/highlight/detail?id=2659116094","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659116094?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:56","pubTimestamp":1786654563,"startTime":"0","endTime":"0","summary":"Genelux publishes corporate presentation highlighting Olvi-Vec late-stage ovarian cancer program focused on platinum sensitizationGenelux highlighted its pivotal Phase 3 OnPrime/GOG-3076 trial of Olvi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL2LDKqz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167282","title":"Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167282","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167282?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:33","pubTimestamp":1786653233,"startTime":"0","endTime":"0","summary":"Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.19) by 10.53 percent. This is a 5 percent decrease over losses of $(0.20) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61194954/genelux-q2-eps-0-21-misses-0-19-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Q2 EPS $(0.21) Misses $(0.19) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659167112","title":"Genelux Posts Wider-than-Expected Q2 Loss on Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2659167112","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659167112?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:29","pubTimestamp":1786652975,"startTime":"0","endTime":"0","summary":"Genelux posts wider-than-expected Q2 loss on higher R&D expensesOverviewUS immuno-oncology firm's Q2 net loss widened, missing analyst expectationsIncome from operations for Q2 missed analyst expectat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A16R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4148","PYXS","GNLX","BK4563","IMNM","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659216764","title":"Press Release: Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2659216764","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659216764?lang=en_us&edition=fundamental","pubTime":"2026-08-14 04:20","pubTimestamp":1786652400,"startTime":"0","endTime":"0","summary":"open-label Phase 3 registrational trial being conducted at sites across. the United States, with topline data anticipated in the second half of. -- The trial is evaluating Olvi-Vec followed by platinum-doublet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4139","BK4555","PLTM","BK4099","BK4588","TM","GNLX","BK4604","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659416954","title":"Genelux Q2 FY26 Net Loss Widens to $9.47 Million; Revenue Flat at no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2659416954","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659416954?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:06","pubTimestamp":1786640809,"startTime":"0","endTime":"0","summary":"Genelux Q2 FY26 net loss widens to $9.47 million; revenue flat at no revenueGenelux posted a net loss of $9.47 million in the quarter ended June 30, 2026, widening from $7.46 million a year earlier.Re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL3H6pq7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656928183","title":"Genelux Corp Expected to Post a Loss of 20 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656928183","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656928183?lang=en_us&edition=fundamental","pubTime":"2026-08-01 06:47","pubTimestamp":1785538026,"startTime":"0","endTime":"0","summary":"Genelux Corp <GNLX.OQ> expected to post a loss of20cents a share - Earnings PreviewGenelux CorpGNLX.OQGNLX.Ois expected to  show no change in quarterly revenue when it reports  results on August 3 (es","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X3F3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651316463","title":"Attovia Therapeutics Appoints John W. Smither to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2651316463","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651316463?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:30","pubTimestamp":1784118602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nTUA90FGLJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GNLX","BK4007","MBX","BK4139","ARQT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647955901","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2647955901","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647955901?lang=en_us&edition=fundamental","pubTime":"2026-06-30 21:10","pubTimestamp":1782825009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Genelux Corp. (GNLX) and Abivax SA Sponsored ADR (AB...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-239?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-239?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534135","title":"Genelux Reports Viro-15 Translational Analysis Supports Olvi-vec Immune Activation, Platinum Resensitization in Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534135","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647534135?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:01","pubTimestamp":1782820875,"startTime":"0","endTime":"0","summary":"Genelux reports VIRO-15 translational analysis supports Olvi-Vec immune activation, platinum resensitization in ovarian cancerGenelux published translational and clinical analyses from the Phase 1b/2 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL5Bfjvq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B64PRP62.GBP","BK4112","IE00BKPKM429.USD","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","SG9999014039.USD","LU0314104364.USD","BK4585","LU2210150020.SGD","BK4588","SG9999014021.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","NDAQ","GNLX","IE00BN0W2T93.GBP","LU2095319765.USD","LU2210149790.SGD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645907047","title":"Genelux shareholders elect John Smither to board at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2645907047","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645907047?lang=en_us&edition=fundamental","pubTime":"2026-06-23 04:46","pubTimestamp":1782161193,"startTime":"0","endTime":"0","summary":"Genelux held its annual shareholder meeting on June 16, 2026.Shareholders selected John Smither to serve as a Class I director through the 2029 annual meeting.Shareholders ratified Weinberg & Company, P.A. as independent registered public accounting firm for fiscal 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL30b0jb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640924057","title":"Genelux director Thomas John disposes of 10,000 common shares worth $29,801","url":"https://stock-news.laohu8.com/highlight/detail?id=2640924057","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640924057?lang=en_us&edition=fundamental","pubTime":"2026-06-03 08:35","pubTimestamp":1780446939,"startTime":"0","endTime":"0","summary":"Genelux director Thomas John sold 10,000 common shares on June 1, 2026 at a weighted average price of $2.98.Directly held stake fell to 472,784 shares following the sale.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 02, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDL2DxgtQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux director Thomas John disposes of 10,000 common shares worth $29,801","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633881004","title":"Genelux Corp reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633881004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633881004?lang=en_us&edition=fundamental","pubTime":"2026-05-08 11:38","pubTimestamp":1778211503,"startTime":"0","endTime":"0","summary":"Genelux Corp reports results for the quarter ended March 31 - Earnings SummaryGenelux Corp GNLX.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended March 31, higher than ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177582","title":"Genelux Q1 net loss widens, misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177582?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:58","pubTimestamp":1778187517,"startTime":"0","endTime":"0","summary":"Genelux Q1 net loss widens, misses analyst expectationsOverviewUS immuno-oncology firm's Q1 net loss widened, missing analyst expectationsQ1 loss from operations also missed analyst expectationsOperat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633778321","title":"Genelux Q1 EPS $(0.20), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2633778321","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633778321?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:55","pubTimestamp":1778187340,"startTime":"0","endTime":"0","summary":"Genelux Q1 EPS $(0.20), Inline","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/GNLX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genelux Q1 EPS $(0.20), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172180","title":"Genelux Q1 2026 net loss widens to $8.9 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172180?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:42","pubTimestamp":1778186567,"startTime":"0","endTime":"0","summary":"Genelux posted a net loss of USD 8.93 million for the three months ended March 31, 2026, widening from USD 7.49 million a year earlier.Total operating expenses rose to USD 9.17 million from USD 7.82 million, led by research and development spending of USD 5.78 million versus USD 4.7 million.Cash, cash equivalents, restricted cash, and marketable securities totaled USD 26.3 million as of March 31, 2026; cash runway expected to last into the first quarter of 2027.Business updates included interim lung cancer data for intravenous Olvi-Vec in SCLC  and NSCLC , plus a January underwritten stock offering that raised USD 18.5 million in net proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original con","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8CLpLs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171836","title":"Press Release: Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171836?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184900,"startTime":"0","endTime":"0","summary":"-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --. -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 --. WESTLAKE VILLAGE, Calif., May 07, 2026  -- Genelux Corporation , a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.\"In parallel, we are making steady progress in advancing our manufacturing and operational capabilities to support the continued development of Olvi-Vec and position the Company for potential commercial readiness. Our focus remains on establishing the necessary supply, quality, and organizational infrastructure as our registration-directed programs advance,\" concluded Mr. Zindrick.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","BK4585","BK4211","PFS","TM","BK4139","BK4555","BK4099","BK4588","GNLX","PLTM","03160","BK4195"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genelux.com","stockEarnings":[{"period":"1week","weight":-0.1131},{"period":"1month","weight":-0.2462},{"period":"3month","weight":-0.2741},{"period":"6month","weight":-0.3698},{"period":"1year","weight":-0.7583},{"period":"ytd","weight":-0.5505}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.012999},{"month":2,"riseRate":0.75,"avgChangeRate":0.366223},{"month":3,"riseRate":0.25,"avgChangeRate":0.051084},{"month":4,"riseRate":0.25,"avgChangeRate":-0.136176},{"month":5,"riseRate":0.5,"avgChangeRate":0.009441},{"month":6,"riseRate":0.5,"avgChangeRate":0.023833},{"month":7,"riseRate":0.25,"avgChangeRate":-0.04953},{"month":8,"riseRate":0.5,"avgChangeRate":0.033045},{"month":9,"riseRate":0.75,"avgChangeRate":0.083435},{"month":10,"riseRate":0.5,"avgChangeRate":0.17427},{"month":11,"riseRate":0,"avgChangeRate":-0.178511},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053731}],"exchange":"NASDAQ","name":"Genelux Corporation","nameEN":"Genelux Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genelux Corporation,GNLX,Genelux Corporation股票,Genelux Corporation股票老虎,Genelux Corporation股票老虎国际,Genelux Corporation行情,Genelux Corporation股票行情,Genelux Corporation股价,Genelux Corporation股市,Genelux Corporation股票价格,Genelux Corporation股票交易,Genelux Corporation股票购买,Genelux Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction